Avanir Pharmaceuticals

The Salk Institute for Biological Studies

Selective Genetics, Inc.

Other

The Whittier Institute for Diabetes & Endocrinology

Ciblex Corporation

Roger Williams General Hospital

Collateral Therapeutics

Avanir Pharmaceutials

Andrew Baird

Douglas A. Lappi

Andrew J Baird

Robert Z Florkiewicz

Wenbin Ying

Jagadish C Sircar

Federico C A Gaeta

Jerry Anchin

Sunil Kumar K C

David Larocca

Peter Bohlen

Denis Gospodarowicz

Sunil Kumar Kc

Nicholas C Ling

Paul D Kassner

Frederick S Esch

Wendy Johnson

Douglas A Lappi

Ann Logan

David T Curiel

Paul Calabresi

Barbara A Sosnowski

Glenn Francis Pierce

A Raymond Frackelton, Jr

Martin Berry

Joanne T Douglas

Buck E Rogers

Ana Maria Gonzalez

Grai Andreason

Sunil Mumar K C

Dale E Warnock

Jeffrey W Clark

Julie G Beitz

Ana-Maria Gonzalez

Michael Philip Nova

Federico CA Gaeta

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Method for screening an agent that modulates activity of macrophage migration inhibitory factor

Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Process for the preparation of inhibitors of macrophage migration inhibitory factor

Filamentous phage particles displaying a ligand on their surface are used to deliver a therapeutic gene to a cell. The ligand is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.

Receptor-mediated gene delivery using bacteriophage vectors

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures:including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures:  including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Inhibitors of macrophase migration inhibitory factor and methods for identifying the same

Growing community of inventors

San Diego, CA, United States of America

Andrew J Baird